GSK Investigational Site

Manchester, Lancashire M8 5RB

0 studies enrolling now · 14 studies all time

What they study most

Arthritis, Rheumatoid, HIV Infection, Infection, Human Immunodeficiency Virus I, Lymphoma, Non-Hodgkin, Menopausal and Female Climacteric States, Neoplasms, Neoplasms, Breast, Neoplasms, Head and Neck, Neoplasms, Prostate, Pulmonary Disease, Chronic Obstructive, Sarcoma, Soft Tissue

Studies at this site

• Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer — Stopped early
• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects — Completed
• Study Of Ispinesib In Subjects With Breast Cancer — Completed
• Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study) — Completed
• GW873140 In Combination With Kaletra In HIV Infected Subjects — Stopped early
• GW873140 In Combination With Combivir In HIV Infected Subjects — Stopped early
• COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed
• Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy — Completed